Cell-targeted PD-1 agonists are potent NK-cell inhibitors.

ABSTRACT:

Background

The programmed cell death protein 1 (PDCD1 or PD-1) is a key regulatory immune checkpoint and a major target for therapeutic intervention. In oncology, antibodies blocking the PD-1 pathway are used to activate immune cells to promote anti tumour immunity while in immune-mediated inflammatory diseases, PD-1 agonist molecules have the potential to achieve immune suppression. NK cells are a specialised population of innate lymphocytes able to recognize a large range of distressed cells including damaged tissues in autoimmune and inflammatory conditions. Of note, NK cells can upregulate PD-1 expression upon activation and their effector functions can be modulated by the PD-1 signalling pathway.

Methods

We have generated a novel bispecific inhibitory molecule, comprise

SUBMITTER: Pope HC 

PROVIDER: S-EPMC12412223 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature